JP2004507712A5 - - Google Patents

Info

Publication number

JP2004507712A5

JP2004507712A5 JP2001555784A JP2001555784A JP2004507712A5 JP 2004507712 A5 JP2004507712 A5 JP 2004507712A5 JP 2001555784 A JP2001555784 A JP 2001555784A JP 2001555784 A JP2001555784 A JP 2001555784A JP 2004507712 A5 JP2004507712 A5 JP 2004507712A5

Authority

JP

Japan

Prior art keywords

dhea

tissue

synthesis

treating

fluid

Prior art date

2001-01-26

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 11
• FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 9
• 229960002847 prasterone Drugs 0.000 description 9
• 230000015572 biosynthetic process Effects 0.000 description 8
• 150000001875 compounds Chemical class 0.000 description 5
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
• 238000000034 method Methods 0.000 description 5
• 230000002981 neuropathic effect Effects 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 239000000523 sample Substances 0.000 description 4
• 210000001130 astrocyte Anatomy 0.000 description 3
• 210000001124 body fluid Anatomy 0.000 description 3
• 201000010099 disease Diseases 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 210000004248 oligodendroglia Anatomy 0.000 description 3
• 230000036542 oxidative stress Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 239000010839 body fluid Substances 0.000 description 2
• 210000004027 cell Anatomy 0.000 description 2
• 239000000203 mixture Substances 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 239000013068 control sample Substances 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 230000000694 effects Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 230000000051 modifying effect Effects 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1